Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment

Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment
Mirvetuximab soravtansine (IMGN853), an investigational antibody-drug conjugate, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of ovarian cancer patients, ImmunoGenthe therapy’s maker, announced. The designation is for the treatment of ovarian cancer patients positive for folate receptor alpha (FRα), who aren't responding to platinum-based chemotherapy, and for whom single-agent therapy is adequate as the next line of treatment. It will support the development of mirvetuximab, speed its review and, depending on how it performs in clinical trials, expedite its entry into the market. Mirvetuximab soravtansine is an investigational treatment for patients with FRα-positive cancer, including ovarian and endometrial cancer. It is an antibody-drug conjugate that targets FRα-positive cancer cells and kills them with a toxic compound called DM4. “We are pleased the FDA has granted Fast Track designation for mirvetuximab soravtansine,”
Subscribe or to access all post and page content.